Group 1 - The core viewpoint of the news is that Spring Medical experienced a decline in stock price and significant financing activity on October 10, with a net financing outflow of 109.77 million yuan [1] - On October 10, Spring Medical's stock fell by 2.80%, with a trading volume of 53.165 million yuan [1] - The financing balance of Spring Medical reached 36.93 million yuan, accounting for 0.55% of its market capitalization, indicating a high level of financing activity compared to the past year [1] Group 2 - Spring Medical, established on February 12, 1998, specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products being joint prosthetics and spinal implants [2] - As of June 30, Spring Medical reported a revenue of 488 million yuan for the first half of 2025, representing a year-on-year growth of 28.27%, and a net profit of 114 million yuan, up 44.85% year-on-year [2] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [3] Group 3 - As of June 30, 2025, the number of shareholders in Spring Medical decreased by 17.57% to 5,920, while the average circulating shares per person increased by 341.41% to 48,836 shares [2] - Among the top ten circulating shareholders, Ping An Low Carbon Economy Mixed A (009878) increased its holdings by 2.77 million shares, while Southern Medical Health Flexible Allocation Mixed A (000452) entered the list as a new shareholder with 1.603 million shares [3]

Core Viewpoint - The semi-annual report performance meets expectations, with domestic business showing recovery growth and overseas business continuing rapid growth. Profit growth outpaces revenue growth primarily due to internal cost reduction and efficiency improvement, leading to a steady enhancement in profitability [1] Financial Performance - In the first half of the year, the company achieved revenue of 488 million yuan, a year-on-year increase of 28.27%, and a net profit attributable to the parent company of 114 million yuan, a year-on-year increase of 44.85%. The net profit after deducting non-recurring items was 106 million yuan, a year-on-year increase of 61.09% [2] - The basic earnings per share were 0.30 yuan per share [3] Quarterly Analysis - In Q2, the company achieved revenue of 258 million yuan, a year-on-year increase of 62.85% and a quarter-on-quarter increase of 12.14%. The net profit attributable to the parent company was 56 million yuan, a year-on-year increase of 136.70% [4] - The profit growth rate exceeded the revenue growth rate due to internal cost reduction and efficiency improvements. The company recorded credit impairment losses and asset impairment losses of 39.33 million yuan in the first half, compared to 11.02 million yuan in the same period last year [4] Outlook for the Second Half - The domestic business is expected to continue its recovery growth, while overseas business is anticipated to maintain rapid growth. The impact of joint procurement price reductions is expected to be cleared, and the company is likely to sustain high growth trends in Q3 and Q4 due to low performance baselines from the previous year [5] Profitability and Cost Management - The gross profit margin decreased to 67.09%, down 4.43 percentage points, mainly due to price reductions from joint procurement. The sales expense ratio decreased significantly to 19.74%, down 9.59 percentage points, attributed to reduced market development costs [6] - The net cash flow from operating activities was 141 million yuan, compared to a negative 69 million yuan in the same period last year, mainly due to increased customer payments. The accounts receivable turnover days decreased to 88.8 days, down 90.1 days year-on-year, indicating improved collection efficiency [6] Long-term Growth Potential - In the short term, the company is expected to reach a performance inflection point, with overseas business likely to continue expanding. The company has strong R&D and production capabilities, with new products in sports medicine, robotics, and dentistry expected to contribute to future growth [7] - Revenue projections for 2025-2027 are 1.111 billion yuan, 1.302 billion yuan, and 1.529 billion yuan, representing year-on-year growth of 37.9%, 17.2%, and 17.4% respectively. Net profit attributable to the parent company is projected to be 238 million yuan, 280 million yuan, and 331 million yuan, with year-on-year growth of 90.8%, 17.4%, and 18.2% respectively [7]

Core Viewpoint - Spring Medical experienced a decline of 2.80% on October 10, with a trading volume of 53.165 million yuan and a market capitalization of 8.922 billion yuan [1] Company Overview - Spring Medical is a leading domestic orthopedic medical device manufacturer, focusing on the research, production, and sales of implantable orthopedic medical devices, including oral metal and invisible orthodontics, as well as oral implants and restorations [2][5] - The company is located in Tongzhou District, Beijing, and was established on February 12, 1998, with its listing date on December 30, 2021 [7][8] - Main products include joint prosthetics covering hip, knee, shoulder, and elbow joints, and a full range of spinal implant products [5][8] Recent Developments - The company is in the design and inspection phase for a customized porous tantalum dental implant product [2] - Spring Medical has introduced various types of 3D printing equipment, including EBM and MJF devices, to advance the development of customized prosthetic products [2][3] - The company has been recognized as a "specialized and innovative" small giant enterprise by the Ministry of Industry and Information Technology, indicating its strong market position and innovation capabilities [3] Financial Performance - For the first half of 2025, Spring Medical achieved operating revenue of 488 million yuan, representing a year-on-year growth of 28.27%, and a net profit attributable to shareholders of 114 million yuan, up 44.85% year-on-year [8] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan in the last three years [8] Shareholder Structure - As of June 30, 2025, the top ten circulating shareholders include Ping An Low Carbon Economy Mixed A and Southern Medical Health Flexible Allocation Mixed A, with notable changes in holdings [9]

截至6月30日，春立医疗股东户数5920.00，较上期减少17.57%；人均流通股48836股，较上期增加 341.41%。2025年1月-6月，春立医疗实现营业收入4.88亿元，同比增长28.27%；归母净利润1.14亿元， 同比增长44.85%。 分红方面，春立医疗A股上市后累计派现3.59亿元。近三年，累计派现3.09亿元。 机构持仓方面，截止2025年6月30日，春立医疗十大流通股东中，平安低碳经济混合A（009878）位居 第四大流通股东，持股377.00万股，相比上期增加277.00万股。南方医药保健灵活配置混合A （000452）位居第九大流通股东，持股160.30万股，为新进股东。中庚小盘价值股票（007130）、香港 中央结算有限公司、中庚价值先锋股票（012930）退出十大流通股东之列。 融券方面，春立医疗10月9日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量200.00股，融券余额4786.00元，超过近一年70%分位水平，处于较高位。 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1 ...

截至月份: 2025年9月30日 狀態: 新提交 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01858 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 95,140,500 | RMB | | 1 RMB | | 95,140,500 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 95,140,500 | RMB | | 1 RMB | | 95,140,500 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- ...

Core Viewpoint - Spring Medical experienced a decline of 3.93% on October 9, with a trading volume of 93.15 million yuan and a total market capitalization of 9.179 billion yuan [1] Company Overview - Spring Medical is a leading domestic orthopedic medical device manufacturer, focusing on the research, production, and sales of implantable orthopedic medical devices, including oral metal and invisible orthodontics, as well as oral implants and restorations [2][5] - The company is located in Tongzhou District, Beijing, and was established on February 12, 1998, with its listing date on December 30, 2021 [7][8] - Main products include joint prosthetics covering hip, knee, shoulder, and elbow joints, and a full range of spinal implant products [5][8] Business Development - The company is currently in the design and inspection phase for a customized porous tantalum dental implant product [2] - Spring Medical has introduced various types of 3D printing equipment, including EBM and MJF, to advance the development of customized prosthetic products [2][3] - The company has been recognized as a "specialized and innovative" small giant enterprise, indicating strong innovation capabilities and high market share [3] Financial Performance - For the first half of 2025, Spring Medical achieved operating revenue of 488 million yuan, a year-on-year increase of 28.27%, and a net profit attributable to shareholders of 114 million yuan, up 44.85% year-on-year [8] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan in the last three years [8] Shareholder Structure - As of June 30, 2025, the top ten circulating shareholders include Ping An Low Carbon Economy Mixed A and Southern Medical Health Flexible Allocation Mixed A, with notable changes in holdings [9]

截至月份: 2025年9月30日 狀態: 新提交 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 北京市春立正達醫療器械股份有限公司 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01858 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 95,140,500 | RMB | | 1 RMB | | 95,140,500 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 95,140,500 | RMB | | 1 RMB | | 95,140,500 | | 2. 股份分類 | 普通股 | 股份類 ...

北京市春立正達醫療器械股份有限公司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） 股份代號：1858 中期報告 INTERIM REPORT 僅供識別 北京市春立正達醫療器械股份有限公司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* (a joint stock limited company incorporated in the People's Republic of China with limited liability) Stock code : 1858 For identication purpose only Beijing Chunlizhengda Medical Instruments Co., Ltd. 北京市春立正達醫療器械股份有限公司 * 2025 INTERIM REPORT 中期報告 | 目 錄 | | | --- | --- | | 公司資料 | 2 | | 管理層討論及分析 | 3 | | 企業管治及其他資料 ...

9月30日，春立医疗涨5.06%，截至发稿，报24.93元/股，成交4513.22万元，换手率0.65%，总市值95.62 亿元。 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京市春立正达医疗器械 股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中国公司。该公司主要产品 为关节假体产品及脊柱类植入产品。关节假体产品涵盖髋、膝、肩、肘四大人体关节。脊柱类植入产品 为脊柱内固定系统的全系列产品组合。该公司的产品出口至亚洲、南美洲、非洲、大洋洲及欧洲等多个 国家和地区。主营业务收入构成为：医疗器械产品99.89%，其他(补充)0.11%。 从春立医疗十大流通股东角度 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，南方基金旗下1只基金位居春立医疗十大流通股东。南方医药保健灵活配置混合A （00045 ...

9月30日，春立医疗涨5.06%，截至发稿，报24.93元/股，成交4513.22万元，换手率0.65%，总市值95.62 亿元。 中庚小盘价值股票（007130）基金经理为陈涛、殷乐。 截至发稿，陈涛累计任职时间4年43天，现任基金资产总规模50.18亿元，任职期间最佳基金回报 36.16%， 任职期间最差基金回报7.35%。 殷乐累计任职时间176天，现任基金资产总规模14.64亿元，任职期间最佳基金回报22.3%， 任职期间最 差基金回报22.3%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京市春立正达医疗器械 股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中国公司。该公司主要产品 为关节假体产品及脊柱类植入产品。关节假体产品涵盖髋、膝、肩、肘 ...